Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

442 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma.
Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong AM, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco BJ, Herráez AC, Gronchi A, Sy-Ortin T, Hohenberger P, de Baère T, Cesne AL, Helfre S, Saada-Bouzid E, Anghel RM, Kantor G, Montero A, Loong HH, Vergés R, Kacso G, Austen L, Servois VF, Wardelmann E, Dimitriu M, Said P, Lazar AJ, Bovée JVMG, Péchoux CL, Pápai Z. Bonvalot S, et al. Among authors: de baere t. Int J Radiat Oncol Biol Phys. 2022 Nov 1;114(3):422-432. doi: 10.1016/j.ijrobp.2022.07.001. Epub 2022 Jul 16. Int J Radiat Oncol Biol Phys. 2022. PMID: 35850363 Free article. Clinical Trial.
[Pelvic perfusion for localy advanced tumors].
Bonvalot S, Muret J, Debaere T. Bonvalot S, et al. Bull Cancer. 2009 Jan;96(1):103-9. doi: 10.1684/bdc.2009.0803. Bull Cancer. 2009. PMID: 19211365 Free article. Review. French.
Hyperthermic pelvic perfusion with tumor necrosis factor-α for locally advanced cancers: encouraging results of a phase II study.
Bonvalot S, de Baere T, Mendiboure J, Paci A, Farace F, Drouard-Troalen L, Bonnet L, Hakime A, Bonniaud G, Raynard B, Israel P, Le Cesne A, Eggermont AM, Laplanche A, Muret J. Bonvalot S, et al. Among authors: de baere t. Ann Surg. 2012 Feb;255(2):281-6. doi: 10.1097/SLA.0b013e318242ebe7. Ann Surg. 2012. PMID: 22241290 Clinical Trial.
First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas.
Bonvalot S, Le Pechoux C, De Baere T, Kantor G, Buy X, Stoeckle E, Terrier P, Sargos P, Coindre JM, Lassau N, Ait Sarkouh R, Dimitriu M, Borghi E, Levy L, Deutsch E, Soria JC. Bonvalot S, et al. Among authors: de baere t. Clin Cancer Res. 2017 Feb 15;23(4):908-917. doi: 10.1158/1078-0432.CCR-16-1297. Epub 2016 Oct 6. Clin Cancer Res. 2017. PMID: 27998887 Clinical Trial.
Basic Knowledge in Soft Tissue Sarcoma.
Bourcier K, Le Cesne A, Tselikas L, Adam J, Mir O, Honore C, de Baere T. Bourcier K, et al. Among authors: de baere t. Cardiovasc Intervent Radiol. 2019 Sep;42(9):1255-1261. doi: 10.1007/s00270-019-02259-w. Epub 2019 Jun 24. Cardiovasc Intervent Radiol. 2019. PMID: 31236647 Review.
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.
Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraez AC, Gronchi A, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouzid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z. Bonvalot S, et al. Among authors: de baere t. Lancet Oncol. 2019 Aug;20(8):1148-1159. doi: 10.1016/S1470-2045(19)30326-2. Epub 2019 Jul 8. Lancet Oncol. 2019. PMID: 31296491 Clinical Trial.
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas.
Ducreux MP, Boige V, Leboulleux S, Malka D, Kergoat P, Dromain C, Elias D, de Baere T, Sabourin JC, Duvillard P, Lasser P, Schlumberger M, Baudin E. Ducreux MP, et al. Among authors: de baere t. Oncology. 2006;70(2):134-40. doi: 10.1159/000093004. Epub 2006 Apr 26. Oncology. 2006. PMID: 16645326 Clinical Trial.
442 results